144 related articles for article (PubMed ID: 25617075)
1. Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.
Sibertin-Blanc C; Mancini J; Fabre A; Lagarde A; Del Grande J; Levy N; Seitz JF; Olschwang S; Dahan L
Dig Liver Dis; 2015 Apr; 47(4):331-7. PubMed ID: 25617075
[TBL] [Abstract][Full Text] [Related]
2. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.
Moreno-Muñoz D; de la Haba-Rodríguez JR; Conde F; López-Sánchez LM; Valverde A; Hernández V; Martínez A; Villar C; Gómez-España A; Porras I; Rodríguez-Ariza A; Aranda E
Eur J Clin Invest; 2015 Dec; 45(12):1325-32. PubMed ID: 26509357
[TBL] [Abstract][Full Text] [Related]
4. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
6. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
7. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.
Etienne-Grimaldi MC; Formento P; Degeorges A; Pierga JY; Delva R; Pivot X; Dalenc F; Espié M; Veyret C; Formento JL; Francoual M; Piutti M; de Crémoux P; Milano G
Br J Clin Pharmacol; 2011 Jun; 71(6):921-8. PubMed ID: 21204912
[TBL] [Abstract][Full Text] [Related]
8. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer.
Sohn BS; Park SJ; Kim JE; Kim KP; Hong YS; Suh C; Kim YS; Kim SY; Im SA; Kim SY; Kim JH; Ahn JB; Park YS; Kim TW
Oncology; 2014; 87(5):280-92. PubMed ID: 25139485
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Cho YY; Moon JH; Park JY; Jeon SW; Lee IT; Choi GS; Jun SH
Clin Cancer Res; 2008 Jan; 14(1):62-6. PubMed ID: 18172253
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
11. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
12. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
Ferroni P; Palmirotta R; Riondino S; De Marchis ML; Nardecchia A; Formica V; Guadagni F; Roselli M
Thromb Haemost; 2016 Jan; 115(1):143-51. PubMed ID: 26336029
[TBL] [Abstract][Full Text] [Related]
13. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
[TBL] [Abstract][Full Text] [Related]
14. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer.
Morita S; Uehara K; Nakayama G; Shibata T; Oguri T; Inada-Inoue M; Shimokata T; Sugishita M; Mitsuma A; Ando Y
Cancer Chemother Pharmacol; 2013 Feb; 71(2):405-11. PubMed ID: 23161411
[TBL] [Abstract][Full Text] [Related]
15. A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer.
Absenger G; Szkandera J; Stotz M; Pichler M; Winder T; Langsenlehner T; Langsenlehner U; Samonigg H; Renner W; Gerger A
Mol Carcinog; 2013 Nov; 52 Suppl 1():E96-102. PubMed ID: 23625573
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor single-nucleotide polymorphism in gallbladder cancer.
Mishra K; Behari A; Kapoor VK; Khan MS; Prakash S; Agrawal S
J Gastroenterol Hepatol; 2013 Oct; 28(10):1678-85. PubMed ID: 23962084
[TBL] [Abstract][Full Text] [Related]
17. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
[TBL] [Abstract][Full Text] [Related]
18. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]